Law360, New York (January 02, 2007, 12:00 AM ET) -- In a blow to a group of generic drug makers, a U.S. appeals court has affirmed a lower court’s decision that upheld Eli Lilly & Co.’s patent on blockbuster schizophrenia drug Zyprexa.
The ruling by the U.S. Court of Appeals for the Federal Circuit on Dec. 26 affirmed the U.S. District Court for the Southern District of Indiana’s 2005 decision that came down in Lilly’s favor on all accounts, leaving in effect a patent on Zyprexa that runs through April of 2011.
Lilly Chairman and CEO...
Eli Lilly Scores In Zyprexa Patent Feud
To view the full article, take a free trial now.
